Maravai Lifesciences Holdings, Inc. (MRVI): Shareholders' Equity
$212.38M
As of 2025-12-31
$204.62M
As of 2026-06-30
-27.0%
3-year compound annual growth
+19.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $212.38M | -34.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $325.29M | n/a | 2026-02-26, Balance as of period end |
| 2024-09-30 | $344.90M | n/a | 2025-03-18, Balance as of period end |
| 2024-06-30 | $434.73M | n/a | 2025-03-18, Balance as of period end |
| 2023-12-31 | $416.75M | -23.6% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $545.22M | +72.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $315.50M | +256.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $88.51M | n/a | 2022-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
Compare MRVI, STOK, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗